Acesion Pharma’s Post

Acesion Pharma is proud to announce the publication of our clinical Phase 2 data in the prestigious Nature Medicine Journal. The trial tested our first-in-class SK ion channel inhibitor AP30663's efficacy in converting Atrial Fibrillation (AF) to normal sinus rhythm with an intravenous infusion. AP30663 achieved a class leading 55% conversion rate resulting in a 99.9% probability of superiority over placebo, demonstrating the first-ever proof of mechanism for SK channel inhibition in AF.   In addition, we are pleased to announce the initiation of a Phase 1 trial for AP31969, an oral SK ion channel inhibitor targeting maintenance of sinus rhythm in AF with chronic treatment. We look forward to sharing more updates soon as we continue our work to change the AF treatment landscape.    Read more: https://lnkd.in/du_4bY8Y   #AcesionPharma #AFResearch #CardiacHealth